The Emmes Company LLC
The Emmes Company LLC is a global clinical research organization headquartered in Potomac, Maryland, specializing in providing comprehensive support services for biomedical research, with a focus on clinical trials and public health initiatives. Established in 1977, Emmes offers a wide range of services to federal agencies, particularly the National Institutes of Health (NIH) and its various institutes. These services include biostatistical analysis, epidemiological studies, data management, clinical trial coordination, regulatory support, and operational oversight for large-scale research programs. The company's expertise spans multiple therapeutic areas, including infectious diseases, oncology, transplantation, and rare diseases. Through its federal contract and grant awards, Emmes delivers critical support for complex research initiatives aimed at advancing public health and medical knowledge.
Emmes has secured numerous prime federal contract awards from various NIH institutes, demonstrating its capabilities across a broad spectrum of research domains. Notable contracts include a $99 million award from the National Cancer Institute for clinical trials and information management support, a $37 million contract from the National Institute of Allergy and Infectious Diseases for allergy and asthma research coordination, and multiple awards from the National Institute on Drug Abuse to support substance abuse research initiatives. These contracts typically involve data management, statistical analysis, clinical trial operations, regulatory compliance, and project oversight. Emmes has also received contracts from the Food and Drug Administration for clinical site monitoring services. As a subcontractor, the company has supported various research programs, including work with General Dynamics Information Technology and Index Analytics on projects related to adverse event diagnostics and clinical trial support. Most of these awards are not set aside for specific business types, reflecting Emmes' established expertise in the field.
The Emmes Company LLC has secured both prime and sub federal grant awards, further showcasing its capabilities in supporting complex research initiatives. As a prime grantee, Emmes received a $3.5 million cooperative agreement from the National Institute of Diabetes and Digestive and Kidney Diseases to continue the Collaborative Islet Transplantation Registry. In its role as a sub-grantee, the company has supported various research programs, including the Blood and Marrow Transplant Clinical Trials Network, HIV cure research, and studies on sickle cell disease. These sub-grant awards involve partnerships with academic institutions such as the Medical College of Wisconsin, Yale University, and the University of California, San Francisco. The grants span multiple NIH institutes and focus on areas such as transplantation, HIV/AIDS, and cancer prevention research. Emmes' contributions typically include data coordination, statistical analysis, and overall project management support for these grant-funded initiatives.
The Emmes Company LLC holds several significant federal contract Indefinite Delivery Vehicles (IDVs) that facilitate its ongoing support of government research initiatives. A notable IDV is the $545 million Comprehensive and Rapid Response for NIAID Research Programs contract, under which Emmes provides a broad range of services including clinical trials support, data management, and regulatory compliance assistance. The company also holds a $31 million IDV with the National Institute on Drug Abuse for data, statistics, and clinical trial support services, and a $46 million vehicle to serve as the Clinical Coordinating Center for NIDA's Clinical Trials Network. Additionally, Emmes has a $4 million IDV with the National Human Genome Research Institute for clinical research support and collaboration services. These IDVs enable various NIH institutes to efficiently procure Emmes' specialized services across multiple research programs and studies, leveraging the company's expertise in managing complex, multi-site clinical trials and research initiatives. Task orders issued under these IDVs cover a wide range of activities, from specific clinical trial support to broader data management and analysis services, further solidifying Emmes' role as a key partner in federal biomedical research efforts.
NBQCBJ6FXBU4 541715
Not listed 401 N Washington St #700, Rockville, MD 20850, USA
4/22/03 11/20/25 Technical Resources International, Inc.
Technical Resources International, Inc., doing business as Technical Resources Intl (TRI), is a minority-owned, woman-owned, Hispanic American-owned small business that specializes in providing comprehensive clinical research support services to federal health agencies. The company offers a wide range of services, including clinical trials execution, regulatory support, research operations, and specialized scientific services critical to advancing medical research and product development. TRI has extensive experience supporting biomedical research initiatives for various agencies, including the National Institutes of Health (NIH), Food and Drug Administration (FDA), Office of the Assistant Secretary for Preparedness and Response (ASPR), and National Library of Medicine (NLM).
Over the past decade, TRI has been awarded over $1.1 billion in federal contracts as a prime contractor, demonstrating its significant role in supporting government health research initiatives. Notable awards include a $333.7 million contract from the National Institute of Allergy and Infectious Diseases (NIAID) for Clinical Research Operations and Management Support, a $317.1 million contract from ASPR for clinical trial planning and execution services, and a $171.4 million contract from the National Cancer Institute (NCI) for clinical trials sponsor and regulatory management support. TRI has also received multiple awards from other NIH institutes for services such as pharmacokinetic analysis, data coordination for clinical studies, and regulatory affairs support. These contracts typically involve complex clinical research services, often focusing on infectious diseases, cancer, and other critical health areas. While most awards are not set aside, TRI has received some contracts designated for small businesses. The company's work spans a wide range of activities, including clinical trial management, regulatory submissions, safety monitoring, data analysis, and scientific support for various research programs.
TRI holds several significant Indefinite Delivery Vehicles (IDVs) that enable rapid procurement of its services across federal health agencies. These include a $548 million multiple-award IDV with NCI for the Cancer Trials Support Unit, a $545.4 million single-award IDV with NIAID for comprehensive and rapid response to research programs, a $400 million single-award IDV with ASPR for clinical trials planning and execution, and a $364.5 million multiple-award IDV with NIAID for preclinical and translational vaccine development services. These IDVs cover a wide range of services, from clinical trial support and regulatory affairs to vaccine development and data management. Task orders issued under these vehicles have supported critical research initiatives in areas such as HIV, cancer, and emerging infectious diseases. For example, under the ASPR IDV, TRI has received task orders for clinical research support services, including project management, site selection and monitoring, specimen and product management, and regulatory affairs. The NIAID IDVs have facilitated rapid response to research needs, including support for clinical trials, manufacturing and controls, nonclinical animal studies, analytics, bioinformatics, and regulatory services.
FAA2LVENETH4 541715
Not listed 6500 Rock Spring Dr #650, Bethesda, MD 20817, USA
9/27/01 7/24/25 Navitas Clinical Research Inc.
Navitas Clinical Research Inc., doing business as K A I, is a full service contract research organization and health research company that provides clinical trials management, research and operations support, training, database maintenance, and other services to assist federal agencies and pharmaceutical/academic clients in bringing new drug treatments and interventions to market.
Through past prime federal contract awards, Navitas Clinical Research Inc. has provided clinical studies management, oversight, monitoring, safety oversight, training, database and systems maintenance, and general administrative services to support clinical research programs funded by the National Institutes of Health's National Heart, Lung, and Blood Institute and the Centers for Disease Control and Prevention. These services were provided through a $7.5 million definitive contract with the National Heart, Lung, and Blood Institute and a $5.6 million definitive contract with the Centers for Disease Control and Prevention Pittsburgh office.
As a subcontractor, Navitas Clinical Research Inc. provided operational, technical and project management support to Science Applications International Corporation and the Frederick National Laboratory for Cancer Research, a federally funded research and development center sponsored by the National Cancer Institute Center for Biomedical Informatics and Information Technology.
Through a federal grant subaward from the University of Maryland, Baltimore, Navitas Clinical Research Inc. provided support for a Phase IIB randomized control trial studying therapeutic hypothermia in patients with acute respiratory distress syndrome.
HA8KGRBJZNM8 541714
Not listed 6 Montgomery Village Ave # 403, Gaithersburg, MD 20879, USA
7/16/03 7/31/25